Overview
Friederike Schmitz practices practicing medicine in Bonn, Germany.
Their clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Loiasis, and Neurotoxicity Syndromes.
They are actively involved in clinical research, co-authoring 12 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Friederike Schmitz
Is Friederike Schmitz a top-rated expert for Multiple Myeloma?
MediFind is an objective health platform that identifies experts based on real-world data. Friederike Schmitz is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Friederike Schmitz participate in research or clinical trials?
Yes. Friederike Schmitz has published 12 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Friederike Schmitz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- LoiasisSchmitz isExperienced. Learn about Loiasis.
- Multiple MyelomaSchmitz isExperienced. Learn about Multiple Myeloma.
- Neurotoxicity SyndromesSchmitz isExperienced. Learn about Neurotoxicity Syndromes.
- Relapsed Refractory Multiple Myeloma (RRMM)